Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5‐Fluorouracil Therapy | Zendy

Beumer Jan H. | Zendy; Chu Edward | Zendy; Allegra Carmen | Zendy; Tanigawara Yusuke | Zendy; Milano Gerard | Zendy; Diasio Robert | Zendy; Kim Tae Won | Zendy; Mathijssen Ron H. | Zendy; Zhang Li | Zendy; Arnold Dirk | Zendy; Muneoka Katsuki | Zendy; Boku Narikazu | Zendy; Joerger Markus | Zendy

Premium

Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5‐Fluorouracil Therapy

Author(s) -

Beumer Jan H.,

Chu Edward,

Allegra Carmen,

Tanigawara Yusuke,

Milano Gerard,

Diasio Robert,

Kim Tae Won,

Mathijssen Ron H.,

Zhang Li,

Arnold Dirk,

Muneoka Katsuki,

Boku Narikazu,

Joerger Markus

Publication year - 2019

Publication title -

clinical pharmacology and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.941

H-Index - 188

eISSN - 1532-6535

pISSN - 0009-9236

DOI - 10.1002/cpt.1124

Subject(s) - clinical toxicology , therapeutic drug monitoring , drug , medicine , fluorouracil , pharmacology , clinical oncology , oncology , therapeutic index , intensive care medicine , toxicology , chemotherapy , cancer , biology

5‐Fluorouracil (5‐FU) is dosed by body surface area, a practice unable to reduce the interindividual variability in exposure. Endorsed by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), we evaluated clinical evidence and strongly recommend TDM for the management of 5‐FU therapy in patients with colorectal or head‐and‐neck cancer receiving common 5‐FU regimens. Our systematic methodology provides a framework to evaluate published evidence in support of TDM recommendations in oncology.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research